2024
Clinical Implications of Low Body Mass Index on Endovascular Lower Extremity Revascularization
Pinto Rodriguez P, Alameddine D, Huttler J, Damara F, Slade M, Cardella J, Guzman R, Chaar C. Clinical Implications of Low Body Mass Index on Endovascular Lower Extremity Revascularization. Annals Of Vascular Surgery 2024, 106: 350-359. PMID: 38810726, DOI: 10.1016/j.avsg.2024.02.031.Peer-Reviewed Original ResearchPeripheral vascular interventionsPeripheral arterial diseaseLower body mass indexUnderweight patientsLong-term outcomesBody mass indexNonobese patientsMass indexRetrospective analysis of patientsRate of thrombotic complicationsHigher 30-day mortalityRates of amputation-free survivalRate of reinterventionOutcomes of patientsPeripheral arterial disease patientsAnalysis of patientsKaplan-Meier analysisImpact of malnutritionBaseline demographic characteristicsChronic limb-threatening ischemiaEpidemic of obesityOptimization of nutritionLonger hospital lengthAdverse limb eventsAmputation-free survivalClinician perspectives regarding CYP2C19 genotype testing in patients with critical limb ischemia: A Delphi approach.
Regan C, Scierka L, Dardik A, Tonnessen B, Iyad Ochoa Chaar C, Ionescu C, Aboian E, Cardella J, Nassiri N, Guzman R, Attaran R, Nagpal S, Shah S, Smolderen K, Mena-Hurtado C. Clinician perspectives regarding CYP2C19 genotype testing in patients with critical limb ischemia: A Delphi approach. Vascular 2024, 17085381241246318. PMID: 38669051, DOI: 10.1177/17085381241246318.Peer-Reviewed Original ResearchDual antiplatelet therapyPeripheral arterial diseaseCYP2C19 testingCYP2C19 mutationsHeterogeneity of treatment effectsPeripheral vascular interventionsConsensus statementKnowledge questionsAntiplatelet therapyGenetic testingVascular surgeryAcademic health systemBarriers to implementationInterquartile rangeCYP2C19 genotype testingVascular diseaseInterventional cardiologyModified Delphi methodPatient's metabolic statusManagement of patientsCritical limb ischemiaPerceived barriersPeripheral vascular diseaseArterial vascular diseaseClinician perspectivesRepresentation of female vascular surgeons in national clinical trial leadership: analysis of trends over 20 years
Kostiuk V, Thaxton C, Loh S, Cardella J, Dardik A, Tonnessen B. Representation of female vascular surgeons in national clinical trial leadership: analysis of trends over 20 years. JVS-Vascular Insights 2024, 2: 100077. DOI: 10.1016/j.jvsvi.2024.100077.Peer-Reviewed Original ResearchClinical trialsFemale vascular surgeonsVascular surgeonsMethods Clinical trialsArtery diseaseClinical trial leadershipSite principal investigatorsVascular conditionsAbdominal aortic aneurysmSurgeon-investigatorInvestigator-led trialsCarotid artery diseasePeripheral arterial diseaseCarotid diseaseProportion of womenVenous thrombectomyBoard certificationAortic aneurysmPercentage of womenIndustry-sponsored trialsTrial leadershipHemodialysis accessSubgroup analysisVascular surgerySurgeons
2023
The Utilization of Protamine during Peripheral Vascular Interventions in the VQI
Ali S, Shebl F, Aboian E, Strosberg D, Fischer U, Cardella J, Guzman R, Ochoa Chaar C. The Utilization of Protamine during Peripheral Vascular Interventions in the VQI. Annals Of Vascular Surgery 2023, 101: 72-79. PMID: 38110083, DOI: 10.1016/j.avsg.2023.10.019.Peer-Reviewed Original ResearchPeripheral vascular interventionsAdjusted rate ratiosProtamine useCardiac complicationsPropensity matchingVascular interventionsChronic obstructive pulmonary diseasePropensity scoreCharacteristics of patientsPeripheral arterial diseaseCongestive heart failureObstructive pulmonary diseaseMultivariable Poisson regressionUse of protamineSignificant differencesMedical comorbiditiesP2Y12 inhibitorsPerioperative bleedingPerioperative medicationsPerioperative outcomesDistal embolizationPatient comorbiditiesCarotid surgeryHeart failurePulmonary disease